The stock of Aurinia Pharmaceuticals Inc (AUPH) has gone up by 13.36% for the week, with a 18.20% rise in the past month and a -5.39% drop in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are 4.72% for AUPH. The simple moving average for the last 20 days is 14.06% for AUPH stock, with a simple moving average of -6.24% for the last 200 days.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
The 36-month beta value for AUPH is also noteworthy at 1.26. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The average price estimated by analysts for AUPH is $13.21, which is $4.35 above than the current price. The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares.
AUPH) stock’s latest price update
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60. However, the company has seen a 13.36% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-03 that Here is how Aurinia Pharmaceuticals (AUPH) and Creative Medical Technology Holdings, Inc. (CELZ) have performed compared to their sector so far this year.
AUPH Trading at 12.13% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.68% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +21.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.77% lower at present.
During the last 5 trading sessions, AUPH rose by +12.15%, which changed the moving average for the period of 200-days by -3.09% in comparison to the 20-day moving average, which settled at $7.85. In addition, Aurinia Pharmaceuticals Inc saw 105.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Jayne David R.W., who sale 8,733 shares at the price of $11.26 back on May 23. After this action, Jayne David R.W. now owns 49,310 shares of Aurinia Pharmaceuticals Inc, valued at $98,334 using the latest closing price.
MacKay-Dunn R. Hector, the Director of Aurinia Pharmaceuticals Inc, sale 4,818 shares at $11.26 during a trade that took place back on May 23, which means that MacKay-Dunn R. Hector is holding 24,225 shares at $54,251 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -84.30 for the present operating margin
- +95.77 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -80.71. The total capital return value is set at -25.07, while invested capital returns managed to touch -24.06. Equity return is now at value -18.94, with -14.80 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 1.99 points at debt to equity in total, while total debt to capital is 1.96. Total debt to assets is 1.72, with long-term debt to equity ratio resting at 1.76. Finally, the long-term debt to capital ratio is 1.73.
When we switch over and look at the enterprise to sales, we see a ratio of 5.37, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 9.28 and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.60.
Conclusion
In summary, Aurinia Pharmaceuticals Inc (AUPH) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
